Case Study: Record-Breaking Engaement for a Rare Disease Treatment

Launching a First-of-Its-Kind Therapy on Digital and Social

Overview

A rare skin condition has long lacked effective treatment options, leaving patients and caregivers with significant unmet needs. Launching the first FDA-approved therapy designed for this condition marked a monumental step forward in rare disease care.

Challenge

A global pharmaceutical company aimed to introduce a topical treatment for Epidermolysis Bullosa while overcoming the challenges of engaging a niche audience, educating healthcare providers unfamiliar with the condition, and sensitively addressing patient and caregiver needs.

Solution

LiveWorld partnered with the brand to:

Conduct deep research to identify active patient communities and ideal communication channels.

Develop targeted messaging pillars addressing FAQs, caregiver support, and proper use of the therapy.

Deploy an omnichannel media strategy integrating digital, paid social, and paid search to reach both healthcare providers and consumers.

Results

This innovative campaign not only raised awareness of Epidermolysis Bullosa but also built an engaged community, setting a new standard for rare disease treatment launches. It showcased the power of social media in reaching and mobilizing a highly targeted patient population, paving the way for a successful product launch.

24K New Users

Attracted 24,000 new users to the branded website, with an average session time exceeding 2 minutes.

$4.09 CPA

Achieved an industry-low average CPA.

87.2k volume
1.4 M interactions

Drove unmatched results among rare disease brands in the corporate portfolio.

Case Study Rare Disease #1